This follows post #3 rather than contradicting it. Date every claim. Positions in this subcategory have moved repeatedly and the archive keeps posts permanently.
The question in the title: EMA product information as a primary source — does this still hold? I will give what I have already checked below so nobody repeats it.
Something about EMA product information does not reconcile and I would like a second pair of eyes before I decide which half is wrong.
Two sources, both reputable, giving figures that cannot both be right unless they are measuring different quantities. My suspicion is that they are, and I cannot see how.
Taking the opening post at face value and following it one step further.
Regional stock held inside the union removes a customs question entirely for intra-union movement, which is a practical difference rather than a legal opinion.
Everything in the opening post holds. The case it does not cover is the one I have.
The reason EMA product information is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the other is silent.
EMA product information: I would want to see the raw numbers rather than the summary before agreeing. Summaries lose exactly the information that would settle this.
The claim about EMA product information upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post says "causes".
Reimbursement is decided nationally and varies substantially between member states for the same authorised product.
Someone should write this up properly, and it should probably not be me.
Reading this EMA product information thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.
EMA product information is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is being asked for.
Source for the EMA product information figure, since it was asked for. It is in the discussion rather than the abstract, which is why the version circulating is stronger than the paper is.
Reading the surrounding paragraph is worth the two minutes. The authors are more careful than their summarisers.
This follows post #12 rather than contradicting it.
The public assessment report published at authorisation is one of the best free technical documents available on any of these compounds and it is rarely cited here.
Netherlands: CBG-MEB implements framework. GPs are first point of contact. Insurance coverage for weight management is conditional on structured lifestyle programme participation.
That is the version I use. It may not be the version that is correct.
For anyone finding this later: the short answer on EMA product information is that it depends on one thing, and the rest of the thread is people identifying which thing.
I keep a log for EMA product information specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing and settled it.
Picking up post #16: that is the part I would want checked first.
EMA is the regulator with national implementation. Licensed incretin analogues are prescription-only across the EU, with some variation in specific approvals by member state.
That is what the documentation says. What happens in practice is usually close.
On post #18 — agreed on the reasoning, with one qualification.
Worth separating EMA product information as a question about the compound from EMA product information as a question about the documentation. They get answered by different people and only one of them is answerable here.
Language versions of the product information are all official and occasionally differ in emphasis. Where a detail matters, reading two is not paranoid.
A request rather than an answer: could whoever has the primary source for EMA product information post it? I have seen the claim three times this month and each version had lost a qualifier.
Thank you for taking the time. That was more work than a reply usually is.
Post #23 describes the usual case. This is about the unusual one.
Two claims get bundled together under EMA product information and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Adding the measurement that post #27 says would settle it.
Members outside the union should note that essentially none of this transfers, including the parts phrased generally.
Noting that the question and the thing people usually mean by it are different.
I read post #27 twice before replying, because I had assumed the opposite.
I would rather this thread reach "we do not know" about EMA product information than reach a confident answer that nobody can support when asked.
Correcting a stale claim here is more valuable than adding a new one, because the stale claims are what people find first.
One more caveat and then I will stop qualifying: the sample selected itself.